Refilling Your Prescribed GLP-1 vs. Buying Compounded Semaglutide Online: What Patients Should Know

If you are already established on a branded GLP-1 medication like Ozempic, Wegovy, Rybelsus, or Mounjaro and simply need a refill at your current dose, that is a fundamentally different medical transaction than enrolling in an online compounding program that ships semaglutide or tirzepatide under a membership model. The FDA has raised specific concerns about compounded GLP-1 products that patients deserve to understand before making a choice. Dr. Refills supports same-dose continuation of FDA-approved branded GLP-1 medications only — no new starts, no dose changes, compounded products not applicable.

Already on a Branded GLP-1 and Need a Refill?

If you have been stable on Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound at the same dose for 3 or more months, Dr. Iwan Nyotowidjojo, MD — ABIM board-certified in Internal Medicine — can review your refill request, often within 1 hour. Flat $59 fee for a 30-day supply request, $79 for 90-day. No charge if not approved. Prescription sent to your own retail pharmacy.

Start my refill →

What Exactly Is Compounded Semaglutide, and Why Are People Buying It?

Compounding is a longstanding, legitimate pharmacy practice in which a licensed pharmacist — or a compounding facility — prepares a customized medication for a specific patient. Traditionally, compounding fills gaps the commercial drug market cannot: a child who needs a liquid form of a tablet-only drug, a patient with an allergy to a commercial formulation's inactive ingredient, or someone who requires a dose that no manufacturer produces. That is the core purpose the law envisions.

GLP-1 receptor agonists like semaglutide and tirzepatide became household names as their branded versions — Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound — faced significant and sustained supply shortages starting in 2022 and extending into 2024. Under federal law, when the FDA places a drug on its official shortage list, compounding pharmacies gain expanded authority to prepare copies of the shortage drug. This created a legal window during which compounded semaglutide and tirzepatide became widely available through online platforms, typically via monthly membership subscriptions that include physician consultations, dose escalation protocols, and home delivery of injectable pens or vials.

The business model is convenient and, for many patients, was their only accessible option during shortage periods. It is worth acknowledging that straightforwardly.

What Has the FDA Said About Compounded GLP-1 Products?

As shortage conditions evolved, the FDA took a series of notable regulatory actions. According to the FDA's own public communications, the agency determined that the shortage of semaglutide injection products had been resolved and subsequently notified outsourcing facilities and state-licensed pharmacies that they should cease compounding copies of those products. The FDA has also published guidance stating that compounded drugs are not FDA-approved — meaning they have not gone through the same review process for safety, efficacy, and manufacturing quality that branded drugs have completed.

According to the FDA, compounded drugs do not undergo FDA premarket review for safety, efficacy, or manufacturing quality, regardless of the reputation of the compounding pharmacy. Patients considering compounded GLP-1 products should review the FDA's current guidance at fda.gov before making a decision.

The FDA has also noted concerns about products marketed as "semaglutide" that contained semaglutide sodium or semaglutide acetate — salt forms that differ from the active ingredient in FDA-approved products, which uses semaglutide base. The agency stated it was not aware of evidence establishing that those salt forms are safe or effective. This is a technical but meaningful distinction, and the FDA's communications on this topic are publicly available for patients who want to read the primary source.

None of this means every compounding pharmacy is operating irresponsibly. Many state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities maintain high standards. The regulatory concern is systemic — about the oversight structure — rather than a blanket indictment of individual compounders. Patients should make their own informed decisions after reading current FDA guidance and speaking with their own physician.

How Do Compounding Subscription Platforms Differ From a Simple Prescription Refill?

Understanding the distinction requires looking at what each model actually does.

Feature	Compounding Subscription Platform	Dr. Refills (Branded Refill Only)
Product dispensed	Compounded semaglutide or tirzepatide (not FDA-approved)	FDA-approved branded medication (e.g., Ozempic, Wegovy, Mounjaro, Zepbound)
New patient starts	Often yes — evaluation and initiation included	No — established patients only (3+ months stability required)
Dose titration	Often built into the program	No — same dose as previously prescribed only
Delivery model	Shipped directly to patient (cold chain logistics)	Prescription sent to patient's own retail or mail-order pharmacy
Pricing model	Monthly or quarterly membership, varies by platform	$59 flat (30-day) / $79 flat (90-day), no charge if not approved
FDA approval status of product	Not FDA-approved	FDA-approved
Best suited for	New patients seeking initiation or titration support; patients whose insurance does not cover branded GLP-1s	Established patients who already have a dose that works, want a convenient refill, and prefer their own pharmacy

Who Are the Compounding Platforms, and What Do They Offer?

Several well-known telehealth companies have offered compounded semaglutide or tirzepatide programs. Because these are real businesses, it is important to be accurate and fair rather than dismissive.

Hims & Hers has publicly offered compounded semaglutide on its platform, as published on their website. They have marketed a personalized program with physician consultation included.

Ro has offered Body Program subscriptions that have included GLP-1 medications, as described on their site at the time of writing.

Noom Med and Found have each offered medically supervised weight management programs incorporating GLP-1 medications, as described on their respective websites.

LifeMD and Sesame have also offered GLP-1 consultations and, in some cases, compounded options, as noted on their platforms.

All pricing, availability, and specific program structures from these companies should be verified directly on their current websites, as policies in this space change frequently. As published at the time of writing, subscription costs across platforms vary considerably. These companies provide legitimate medical services and may be the more appropriate choice for patients who are not yet established on a GLP-1, who need titration support, or whose insurance situation makes branded drugs inaccessible.

Dr. Refills does not compete with what those platforms do for new patients. The service offered here is narrower by design.

What Is Dr. Refills' Specific Role With GLP-1 Medications?

Dr. Refills is an asynchronous telehealth service for same-dose continuation of chronic medications patients are already established on. For GLP-1 medications specifically, the following conditions apply:

You must have been on your current GLP-1 medication and dose for at least 3 months with documented stability
Dr. Refills refills only FDA-approved branded products — Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or similar — not compounded versions
No new starts: if you have never taken a GLP-1 before, this service is not appropriate for initiation
No dose changes: if your prescribing physician has recommended increasing or decreasing your dose, that adjustment should happen under their direct supervision, not through an async refill service
Every request is personally reviewed by Iwan S. Nyotowidjojo, MD, ABIM board-certified in Internal Medicine
Dr. Nyotowidjojo is personally licensed in each state where patients are served

What Safety Screening Happens Before a GLP-1 Refill Is Approved?

Even for a straightforward same-dose refill, GLP-1 medications carry specific safety considerations that require screening. During the intake process, Dr. Nyotowidjojo reviews each patient's history for the following:

Pancreatitis history: GLP-1 receptor agonists have been associated with pancreatitis. A personal history of pancreatitis is a contraindication that must be identified before any refill is approved.
Gallbladder disease: GLP-1 use has been associated with gallbladder-related events. Known gallbladder disease is reviewed as part of the screening process.
Personal or family history of medullary thyroid carcinoma (MTC): GLP-1 receptor agonists carry a boxed warning related to thyroid C-cell tumors in animal studies. Patients or immediate family members with a history of MTC require direct specialist oversight, not an async refill service.
Multiple Endocrine Neoplasia type 2 (MEN2): This hereditary syndrome is associated with MTC risk and is likewise screened as part of the intake process.

If screening identifies any of these concerns, the request will not be approved, and the patient will be directed back to their primary care physician or specialist. No charge applies if a request is not approved.

Established on Ozempic, Wegovy, Mounjaro, or Zepbound?

If you have been stable at the same dose for 3 or more months and simply need a refill sent to your pharmacy — not a new start, not a dose change — Dr. Nyotowidjojo can review your case, often within 1 hour. $59 for 30 days, $79 for 90 days. No charge if not approved. Serving patients in CA, TX, FL, NY, IL, PA, OH, GA, MI, and MN.

Start my refill →

Is an Async Refill Service Right for Every GLP-1 Patient?

Honestly, no — and it is important to say that directly. This service is designed for a specific, narrow use case: the patient who has already done the hard work of finding the right medication and dose with their physician, is doing well, and needs a streamlined way to get a refill when their prescribing doctor is unavailable, when they have moved, or when scheduling an in-person visit is burdensome.

If any of the following describe your situation, please see your primary care physician or a specialist rather than using this service:

You are considering starting a GLP-1 for the first time
You are experiencing new or worsening symptoms that may be related to your medication
You want to change your dose or switch products
You have a history of pancreatitis, significant gallbladder disease, medullary thyroid cancer, or MEN2
You are pregnant, planning pregnancy, or breastfeeding
Your situation is clinically complex in ways that require an ongoing prescriber relationship

New symptoms — especially abdominal pain, nausea, or vomiting that is new or worsening — should prompt a call to your doctor, not a refill request. Anyone experiencing a medical emergency should call 911 immediately.

How Does the Dr. Refills Process Work for a GLP-1 Refill?

Submit your refill request through the secure intake form, including your current medication, dose, prescribing history, and the screening questions about pancreatitis, gallbladder disease, and thyroid/MEN2 history
Dr. Nyotowidjojo personally reviews your request — typically within 1 hour during operating hours
If approved, a prescription for your FDA-approved branded GLP-1 medication is sent electronically to the retail or mail-order pharmacy of your choice
If not approved, you receive a clear explanation and a recommendation to follow up with your own physician — and you are not charged
The flat fee is $59 for a 30-day supply request or $79 for a 90-day supply request, covering unlimited medications per single request

You can also review Dr. Nyotowidjojo's licensure details and the states where he is currently licensed to practice at drrefills.com/licensure.

Frequently Asked Questions

Can Dr. Refills prescribe compounded semaglutide or tirzepatide?

No. Dr. Refills supports same-dose continuation of FDA-approved branded GLP-1 medications only. Compounded semaglutide and compounded tirzepatide are outside the scope of this service. If you are interested in compounded options, that conversation should happen with a physician in an ongoing care relationship who can evaluate your full clinical picture.

I started on compounded semaglutide and want to switch to the branded version. Can Dr. Refills help?

Switching from a compounded product to an FDA-approved branded product — or changing any aspect of your regimen — is a clinical change that falls outside the scope of an async same-dose refill service. Please discuss this transition with your prescribing physician, who can evaluate whether the switch is appropriate and manage it directly.

Why does Dr. Refills require 3 months of stability before refilling a GLP-1?

GLP-1 receptor agonists require a titration period after initiation, during which dose adjustments are common and side effects are most likely to emerge. Three months of stability at the same dose provides reasonable evidence that you are tolerating the medication well and that the current dose is your established therapeutic dose — making same-dose continuation clinically appropriate without in-person re-evaluation.